FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents an isolated rhabdovirus particle for use in oncolytic viral therapy in a patient with glioblastoma, wherein the recovered rhabdovirus particle includes a genome capable of expressing: protein having a sequence which is at least 85 % identical to SEQ ID NO: 1, a protein having a sequence which is at least 85 % identical to SEQ ID NO: 2, a protein having a sequence which is at least 85 % identical to SEQ ID NO: 3, a protein having a sequence which is at least 85 % identical to SEQ ID NO: 4, and a protein having a sequence which is at least 85 % identical to SEQ ID NO: 7. Invention also relates to a kit containing said rhabdovirus particle for treating glioblastoma.
EFFECT: invention widens the range of products for treating glioblastoma.
20 cl, 16 dwg, 1 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE COMPOSITION | 2014 |
|
RU2684211C2 |
| NON-GENETIC MODIFICATION OF ENVELOPED VIRUSES | 2017 |
|
RU2760521C2 |
| NON-REPLICATING VIRUS-DERIVED PARTICLES AND USE THEREOF | 2013 |
|
RU2705556C2 |
| RECOMBINANT VESICULAR STOMATITIS VIRUS EXPRESSING CHIMERIC IL12-GMCSF PROTEIN | 2022 |
|
RU2817896C1 |
| GENE EDITING OF DEEP INTRON MUTATIONS | 2016 |
|
RU2759335C2 |
| RNAi AGENT OPTION | 2018 |
|
RU2789647C2 |
| BACULOVIRUS VECTORS WITH DOUBLE PROMOTER INCLUDING VERTEBRATE PROMOTOR AND BACULOVIRUS PROMOTOR CONTROLLING IMMUNOGENIC FUSED GENE | 2008 |
|
RU2491093C2 |
| FUSED PROTEINS OF CARCINOEMBRYONAL ANTIGEN | 2005 |
|
RU2380375C2 |
| MICROVESICLE AND METHOD FOR ITS PREPARATION | 2014 |
|
RU2693088C2 |
| VIRAL VECTORS WITH CONDITION-DEPENDENT REPLICATION AND THEIR USING | 2001 |
|
RU2301260C2 |
